公开(公告)号：US20210155614A1

公开(公告)日：2021-05-27

申请号：US17165136

申请日：2021-02-02

申请人： Purdue Research Foundation

发明人： Richard M. Van Rijn ,  Mark S. Cushman ,  Markus Lill ,  Robert J. Cassell ,  Amr Hamed Mahmoud Abdallah ,  Mohamed S.A. Elsayed

IPC分类号： C07D409/12 ,  A61P25/32 ,  C07D405/12 ,  C07D417/12

摘要： The present disclosure relates to novel δ-opioid receptor agonists, and the method of making and using the novel δ-opioid receptor agonists. The novel δ-opioid receptor agonists are selective δ-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel δ-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.

公开(公告)号：US11787787B2

公开(公告)日：2023-10-17

申请号：US17165136

申请日：2021-02-02

申请人： Purdue Research Foundation

发明人： Richard M Van Rijn ,  Mark S Cushman ,  Markus Lill ,  Robert J Cassell ,  Amr Hamed Mahmoud Abdallah ,  Mohamed S. A. Elsayed

IPC分类号： C07D409/12 ,  A61P25/32 ,  C07D405/12 ,  C07D417/12

CPC分类号： C07D409/12 ,  A61P25/32 ,  C07D405/12 ,  C07D417/12

摘要： The present disclosure relates to novel δ-opioid receptor agonists, and the method of making and using the novel δ-opioid receptor agonists. The novel δ-opioid receptor agonists are selective δ-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel δ-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.

公开(公告)号：US10954224B2

公开(公告)日：2021-03-23

申请号：US16620907

申请日：2018-06-08

申请人： Purdue Research Foundation

发明人： Richard M Van Rijn ,  Mark S Cushman ,  Markus Lill ,  Robert J Cassell ,  Amr Hamed Mahmoud Abdallah ,  Mohamed S. A. Elsayed

IPC分类号： C07D409/12 ,  A61P25/32 ,  C07D405/12 ,  C07D417/12

摘要： The present disclosure relates to novel δ-opioid receptor agonists, and the method of making and using the novel δ-opioid receptor agonists. The novel δ-opioid receptor agonists are selective δ-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel δ-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.